Protagonist Therapeutics Files Routine 8-K for Disclosure

Ticker: PTGX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1377121

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance

TL;DR

**Protagonist Therapeutics filed a routine 8-K, no major news.**

AI Summary

Protagonist Therapeutics, Inc. filed an 8-K on January 8, 2024, indicating a routine filing for Regulation FD Disclosure and Financial Statements and Exhibits. This filing, with a Commission File Number of 001-37852, does not contain specific financial figures or major corporate events, but rather serves as a procedural update. For investors, this means there's no immediate new information impacting the stock price, but it confirms the company's ongoing compliance with SEC reporting requirements.

Why It Matters

This filing is a standard procedural update, indicating Protagonist Therapeutics is maintaining its regulatory compliance. It doesn't contain new material information that would immediately affect stock valuation.

Risk Assessment

Risk Level: low — This 8-K is a standard regulatory filing with no new material information, posing minimal risk.

Analyst Insight

A smart investor would note this as a routine compliance filing and not expect any immediate stock price movement based solely on this 8-K. Further research into the company's actual financial statements or other material disclosures would be necessary for investment decisions.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Protagonist Therapeutics, Inc.?

This 8-K filing by Protagonist Therapeutics, Inc. is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', as indicated in the 'ITEM INFORMATION' section of the filing.

When was the earliest event reported in this 8-K filing?

The 'Date of Report (Date of earliest event reported)' for this 8-K filing is January 8, 2024.

What is the Commission File Number for Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc.'s Commission File Number, as stated in the filing, is 001-37852.

Where is Protagonist Therapeutics, Inc.'s principal executive office located?

The principal executive office of Protagonist Therapeutics, Inc. is located at 7707 Gateway Blvd., Suite 140, Newark, California 94560-1160.

What is the state of incorporation for Protagonist Therapeutics, Inc.?

Protagonist Therapeutics, Inc. is incorporated in Delaware, as specified under 'State or other jurisdiction of incorporation' in the filing.

Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-08 08:00:47

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On January 8, 2024, Protagonist Therapeutics, Inc. (the "Company") made available an updated corporate presentation. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Protagonist Therapeutics, Inc. Corporate Presentation, as of January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this report, including the exhibits hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: January 8, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing